Skip to Content

Defitelio (defibrotide) Disease Interactions

There is 1 disease interaction with Defitelio (defibrotide):


Defibrotide (applies to Defitelio) bleeding

Major Potential Hazard, Moderate plausibility.

The use of defibrotide may increase the risk of bleeding in patients with hepatic veno-occlusive disease after hematopoietic stem-cell transplantation. Discontinue anticoagulants and fibrinolytic agents prior to defibrotide treatment, and consider delaying the start of defibrotide administration until the effects of the anticoagulant have subsided. It is recommended to withhold therapy with defibrotide in patients with active bleeding and to monitor patients for signs of bleeding. Discontinue treatment with defibrotide in patients that develop bleeding and treat the underlying cause, and provide supportive care until the bleeding has stopped.

Defitelio (defibrotide) drug interactions

There are 136 drug interactions with Defitelio (defibrotide)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.